Somatostatin analogues in the treatment of enteropancreatic neuroendocrine tumors

#3337

Introduction: Enteropancreatic neuroendocrine tumors are rare neoplasms.

Aim(s): The primary endpoint was progression free survival evaluated by RECIST 1.1, secondary endpoints were correlation the relationship between clinical factors and Overall survival.

Materials and methods: Retrospective study in patients with advanced well and moderately differentiated NET’s treated with somatostatin analogues in first line treatment (lanreotide and octreotide) from January 2007 to December 2019. Continuous variables were summarized as arithmetic means and SDs, whereas categorical variables were expressed as frequencies and proportions. The χ2 or Fisher exact test was used for assessing the statistical significance of clinical. The Kaplan–Meier method was used to estimate survival curves. The multivariate Cox proportional hazards regression was used to evaluate independent prognostic factors associated with PFS or OS. All statistical tests were two-sided and P < 0.05 was deemed to be statistically significant.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Correa R

Authors: Sanchez Dominguez G, Jiménez J, Sanchez J, Correa R, Alegria J,

Keywords: enteropancreatic neuroendocrine tumor,